INT226794

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.40
First Reported 2007
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 4
Total Number 10
Disease Relevance 0.52
Pain Relevance 0.24

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

isomerase activity (Srr) lyase activity (Srr) plasma membrane (Srr)
cellular amino acid metabolic process (Srr) cytoplasm (Srr)
Anatomy Link Frequency
pinealocytes 4
brain 1
SRs 1
Srr (Mus musculus)
Pain Link Frequency Relevance Heat
Glutamate 21 99.74 Very High Very High Very High
imagery 10 65.52 Quite High
noradrenaline 7 63.60 Quite High
Neurotransmitter 14 63.04 Quite High
Inflammation 22 36.72 Quite Low
anesthesia 7 5.00 Very Low Very Low Very Low
cytokine 4 5.00 Very Low Very Low Very Low
Inflammatory response 2 5.00 Very Low Very Low Very Low
lidocaine 2 5.00 Very Low Very Low Very Low
headache 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Metastasis 35 98.06 Very High Very High Very High
Non-small-cell Lung Cancer 10 84.16 Quite High
Sunburn 7 82.72 Quite High
Lung Cancer 4 72.48 Quite High
Cancer 30 48.24 Quite Low
Respiratory Syncytial Virus 188 40.24 Quite Low
INFLAMMATION 24 37.24 Quite Low
Infection 60 35.88 Quite Low
Small Cell Lung Cancer 4 35.28 Quite Low
Glioblastoma 7 30.72 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
As shown Fig. 1D, N-GFP SRS fluorescence was associated to cells after one hour of contact at 4°C.
Gene_expression (fluorescence) of SRS
1) Confidence 0.40 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2262139 Disease Relevance 0 Pain Relevance 0
Microtiter plates (Immulon 2HB, ThermoLabsystems) were coated overnight at 4°C with N SRS antigen (200 ng per well in 100 µL carbonate-bicarbonate buffer 0.1 M pH 9.5).
Gene_expression (coated) of N SRS
2) Confidence 0.40 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2262139 Disease Relevance 0 Pain Relevance 0
Both antibodies clearly labeled SRs in photoreceptor terminals (Fig. 2a,c) and pinealocytes (Fig. 2b,d).
Gene_expression (labeled) of SRs in pinealocytes
3) Confidence 0.35 Published 2008 Journal Cell Tissue Res Section Body Doc Link PMC2757586 Disease Relevance 0 Pain Relevance 0
Pinealocyte SRs function in transmitter release
Gene_expression (function) of SRs in Pinealocyte
4) Confidence 0.31 Published 2008 Journal Cell Tissue Res Section Body Doc Link PMC2757586 Disease Relevance 0.08 Pain Relevance 0
The typical RIBEYE B/CtBP2 labeling of the SRs and nuclei (N) is stronger compared with the CtBP1 labeling (nuclei are indicated by white dots in c, d).
Gene_expression (labeling) of SRs
5) Confidence 0.31 Published 2008 Journal Cell Tissue Res Section Body Doc Link PMC2757586 Disease Relevance 0 Pain Relevance 0
SRs were labeled with anti-RIBEYE B (RIB B; examples marked by arrowheads), which, additionally stained nuclei (N).
Gene_expression (labeled) of SRs in SRs
6) Confidence 0.31 Published 2008 Journal Cell Tissue Res Section Body Doc Link PMC2757586 Disease Relevance 0 Pain Relevance 0.03
Dynamic changes of pinealocyte SRs and their associated proteins
Gene_expression (changes) of SRs in pinealocyte
7) Confidence 0.31 Published 2008 Journal Cell Tissue Res Section Body Doc Link PMC2757586 Disease Relevance 0 Pain Relevance 0
Arrowheads in a, b, d, f, g Examples of double-labeling of SRs.
Gene_expression (labeling) of SRs
8) Confidence 0.31 Published 2008 Journal Cell Tissue Res Section Body Doc Link PMC2757586 Disease Relevance 0 Pain Relevance 0
Clear subcellular evidence exists that, in rat pinealocytes, the strongest glutamate labeling is present over SRs (McNulty et al. 1992) and that a sizable glutamate pool is present in the so-called synaptic-like microvesicles that accumulate in terminal swellings of pinealocyte processes where SRs also occur (Redecker 1999).
Gene_expression (present) of SRs in pinealocytes associated with glutamate
9) Confidence 0.31 Published 2008 Journal Cell Tissue Res Section Body Doc Link PMC2757586 Disease Relevance 0 Pain Relevance 0.18
In this trial, patients with 1–4 brain metastases are being treated with 37.5 Gy WBRT +10 doses MGd 5 mg/kg/day during weeks 2 and 3, followed by SRS boost +MGd 5 mg/kg within 14 days of completing WBRT.
Gene_expression (boost) of SRS in brain associated with metastasis
10) Confidence 0.21 Published 2007 Journal International Journal of Nanomedicine Section Body Doc Link PMC2673824 Disease Relevance 0.44 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox